RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

NCT07732634 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Head Cancer
Neck Cancer

Interventions

DRUG: RiMO-301
DRUG: Pembrolizumab
RADIATION: Radiation
PROCEDURE: Surgical resection

Sponsor

University of Illinois at Chicago

Collaborators

[object Object]